Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Perspective Therapeutics (NASDAQ:CATX) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $14.00 price target on the stock.

Several other research firms have also recently weighed in on CATX. Truist Financial started coverage on shares of Perspective Therapeutics in a research report on Monday, November 24th. They set a “buy” rating and a $12.00 price objective on the stock. UBS Group decreased their target price on Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Finally, B. Riley dropped their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and a consensus price target of $11.00.

Perspective Therapeutics Trading Up 4.1%

Perspective Therapeutics stock opened at $2.51 on Tuesday. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $5.39. The company has a market capitalization of $186.59 million, a PE ratio of -2.79 and a beta of 1.18.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.